Despite the presence of extracellular β-amyloid (Aβ) and intracellular tau protein aggregates is an established hall-mark of the AD pathology, the limited scientific evidence on the timing of the molecular cascade leading to AD-related neurodegeneration has made difficult the development of both early diagnostic strategies and effective therapies. This evidence concerns the gene MAPT and Alzheimer disease.